Insulet (NSDQ:PODD) last week touted the publication of new data supporting the benefits of its Omnipod insulin management system, with data supporting the systems’ efficacy at controlling blood glucose levels in patients switching from daily injections or tubed insulin pumps.
Data from the company’s multi-center retrospective study was used in 2 online publications in the Journal of Diabetes Science, Insulet said.
“This study marks the 1st report of glycemic control among a large cohort of patients treated with Omnipod in a real-world clinical setting, with results comparable to those reported for multiple daily insulin injections and other continuous subcutaneous infusion pumps. While the patients we studied showed A1c level improvement overall, it’s significant to note the difference was greatest among those who had the least control of their condition. This suggests that poor glycemic control may be an important consideration for patients when deciding whether to initiate insulin pump therapy versus daily injections,” senior author Dr. Howard Zisser said in a press release.
Data from the company’s 900-patient study indicated a 0.6% reduction in A1c levels for patients previously on MDI therapy and 0.5% lower compared to patients using traditional tubed insulin pumps.
Patients with type 2 diabetes reported A1c levels 1.2% lower after 3 months compared to prior treatment with MDI, Insulet said.
Data from the study also indicated “significant reductions in daily insulin requirement and in the frequency and severity of reported hypoglycemic episodes” in type I and II diabetes patients, according to the company.
“Our mission is to change the way patients and providers manage diabetes. We are proud of these study results and are dedicated to improving the lives of people of all ages with diabetes, including the more than 85,000 members of our growing Podder community worldwide, by helping them live tube-free and without the hassles of multiple daily injections,” CEO Patrick Sullivan said in a prepared statement.